Theratechnologies Inc. (TH) Analysts See $-0.03 EPS

June 14, 2018 - By Hazel Jackson

Analysts expect Theratechnologies Inc. (TSE:TH) to report $-0.03 EPS on July, 11.They anticipate $0.10 EPS change or 76.92 % from last quarter’s $-0.13 EPS. After having $-0.04 EPS previously, Theratechnologies Inc.’s analysts see -25.00 % EPS growth. The stock increased 1.06% or $0.14 during the last trading session, reaching $13.35. About 47,455 shares traded. Theratechnologies Inc. (TSE:TH) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. The company has market cap of $1.02 billion. The Company’s lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: